Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 5/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA3 | P07451 | 2/20 | 0.32 |
| ▸ | CA4 | P22748 | 2/20 | 0.32 |
| ▸ | CA6 | P23280 | 2/20 | 0.32 |
| ▸ | CA5A | P35218 | 2/20 | 0.32 |
| ▸ | CA7 | P43166 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15932260 | 0.95 | CHRM2 (0.46) | CHRM2NFKB1DNM1CA12CA1 | |
| SCHEMBL16219457 | 0.90 | DNM1 (0.42) | CHRM2DNM1TSHRMEN1KMT2A | |
| SCHEMBL3236990 | 0.90 | DNM1 (0.36) | CHRM2DNM1TSHRMEN1KMT2A | |
| SCHEMBL25587421 | 0.88 | CHRM2 (0.31) | CHRM2 | |
| SCHEMBL27220529 | 0.87 | CHRM2 (0.33) | CHRM2DNM1TSHRMEN1KMT2A | |
| SCHEMBL9738325 | 0.82 | TDP1 (0.32) | TDP1 | |
| SCHEMBL5667895 | 0.81 | CYP2D6 (0.32) | — | |
| SCHEMBL13390302 | 0.78 | CHRM2 (0.35) | CHRM2NFKB1TDP1 | |
| SCHEMBL25096033 | 0.78 | — | — | |
| SCHEMBL3794084 | 0.77 | CHRM2 (0.38) | CHRM2NFKB1TDP1DNM1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220127613-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | SAREPTA THERAPEUTICS INC (US) | 2022-04-28 | — | — | US | disclosed |
| US-11208655-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-11198705-B2 | Hybrid Amphotericin B derivatives with reduced toxicity | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2021-12-14 | — | — | US | disclosed |
| US-10882883-B2 | Derivatives of amphotericin B | SFUNGA THERAPEUTICS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20200262858-A1 | DERIVATIVES OF AMPHOTERICIN B | ELION THERAPEUTICS, INC. | 2020-08-20 | — | — | US | disclosed |
| US-20200115709-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-04-16 | — | — | US | disclosed |
| EP-3080170-B1 | INSERTION POLYNORBORNENE-BASED THERMOSET RESINS | TRANSFERT PLUS SEC (CA) | 2020-02-05 | — | — | EP | disclosed |
| US-10344281-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20180223278-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-08-09 | — | — | US | disclosed |
| US-20180223278-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-08-09 | — | — | US | disclosed |
| US-9957290-B2 | Derivatives of amphotericin B | SFUNGA THERAPEUTICS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9790499-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9790499-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20160376587-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2016-12-29 | — | — | US | disclosed |
| US-9278987-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20160009733-A1 | REGULATION OF NITRIC OXIDE RELEASE AND BIOFILM DEVELOPMENT | UNIVERSITY OF WOLLONGONG (AU) | 2016-01-14 | — | — | US | disclosed |
| US-9156855-B2 | Regulation of nitric oxide release and biofilm development | Newsouth Innovation Pty Limited (AU) | 2015-10-13 | — | — | US | disclosed |
| US-20140330006-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | SAREPTA THERAPEUTICS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140221331-A1 | REGULATION OF NITRIC OXIDE RELEASE AND BIOFILM DEVELOPMENT | UNIVERSITY OF WOLLONGONG (AU) | 2014-08-07 | — | — | US | disclosed |
| US-5128408-A | Quaternized amino polyurethane- or polyurethaneurea-polysiloxanes treated with heparin | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 1992-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180223278-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | RTCB, NSUN3, NSUN2 | CHRM2 4812/4885NFKB1 1603/4885TDP1 441/4885 |
| US-11208655-B2 | Functionally-modified oligonucleotides and subunits thereof | RTCB, NSUN3, NSUN2 | CHRM2 4812/4885NFKB1 1603/4885TDP1 441/4885 |
| US-20140330006-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | RTCB, NSUN3, NSUN2 | CHRM2 4812/4885NFKB1 1603/4885TDP1 441/4885 |
| US-10882883-B2 | Derivatives of amphotericin B | C9, ERG28, AMPD3 | CHRM2 1578/4885NFKB1 2527/4885TDP1 4765/4885 |
| US-20200115709-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | RTCB, NSUN3, NSUN2 | CHRM2 4812/4885NFKB1 1603/4885TDP1 441/4885 |
| US-20160009733-A1 | REGULATION OF NITRIC OXIDE RELEASE AND BIOFILM DEVELOPMENT | NOS1, NOS2, NOS3 | CHRM2 2289/4885NFKB1 567/4885TDP1 783/4885 |
| US-10344281-B2 | Functionally-modified oligonucleotides and subunits thereof | RTCB, NSUN3, NSUN2 | CHRM2 4812/4885NFKB1 1603/4885TDP1 441/4885 |
| US-20200262858-A1 | DERIVATIVES OF AMPHOTERICIN B | C9, ERG28, AMPD3 | CHRM2 1578/4885NFKB1 2527/4885TDP1 4765/4885 |
| US-20140221331-A1 | REGULATION OF NITRIC OXIDE RELEASE AND BIOFILM DEVELOPMENT | NOS1, NOS2, NOS3 | CHRM2 2289/4885NFKB1 567/4885TDP1 783/4885 |
| US-20220127613-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | RTCB, NSUN3, NSUN2 | CHRM2 4812/4885NFKB1 1603/4885TDP1 441/4885 |
| US-11198705-B2 | Hybrid Amphotericin B derivatives with reduced toxicity | ERG28, BAK1, MCL1 | CHRM2 4319/4885NFKB1 3230/4885TDP1 3138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.